Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

US job openings in research and development are plunging as the Trump administration ramps up funding cuts to government ...

Merck KGaA's recent stock dip of 13% might scream trouble, but under the hood, things look remarkably solid. Despite a ...

Trump has claimed the move could cut US drug prices by 30 to 80 percent. However, according to German consultancy ...

Merck & Co. got a lukewarm “neutral” rating from Citigroup, along with a price target drop from $115 to $84. Other analysts ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

The company posted better-than-expected earnings as industrial business profit grew 29%. Deutsche Telekom Lifts Guidance After Revenue Beats Market Expectations The full-year outlook raise from the ...

The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic ...

Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion Germany's Merck KGaA said on Thursday ... and it lowered its outlook for the full year due to higher-than ...

Announced a global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt ... today announced its financial results for the first quarter ended March 31, 2025 ...

Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly earnings beats and held firm with its full-year outlook despite ...